Long‐term benefits of rivastigmine in dementia associated with Parkinson's disease: An active treatment extension study
Identifieur interne : 001C18 ( Istex/Corpus ); précédent : 001C17; suivant : 001C19Long‐term benefits of rivastigmine in dementia associated with Parkinson's disease: An active treatment extension study
Auteurs : Werner Poewe ; Erik Wolters ; Murat Emre ; Marco Onofrj ; Chuanchieh Hsu ; Sibel Tekin ; Roger LaneSource :
- Movement Disorders [ 0885-3185 ] ; 2006-04.
English descriptors
Abstract
In patients with dementia associated with Parkinson's disease (PD), the efficacy and safety of rivastigmine, an inhibitor of acetylcholinesterase and butyrylcholinesterase, were previously demonstrated in a 24‐week double‐blind placebo‐controlled trial. Our objective was to determine whether benefits were sustained over the long term. Following the double‐blind trial, all patients were permitted to enter an active treatment extension study, during which they received rivastigmine 3–12 mg/day. Standard safety assessments were performed. Efficacy assessments included the Alzheimer's Disease Assessment Scale cognitive subscale (ADAS‐cog) and other measures of cognition, daily function, neuropsychiatric symptoms, and executive function. Of 433 patients who completed the double‐blind trial, 334 entered and 273 completed the active treatment extension. At 48 weeks, the mean ADAS‐cog score for the whole group improved by 2 points above baseline. Placebo patients switching to rivastigmine for the active treatment extension experienced a mean cognitive improvement similar to that of the original rivastigmine group during the double‐blind trial. The adverse event profile was comparable to that seen in the double‐blind trial. Long‐term rivastigmine treatment appeared well tolerated and may provide sustained benefits in dementia associated with PD patients who remain on treatment for up to 48 weeks. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20700
Links to Exploration step
ISTEX:FF4664716C5C713577D1CEB95BD89D6BD466E804Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long‐term benefits of rivastigmine in dementia associated with Parkinson's disease: An active treatment extension study</title><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Innsbruck Medical University, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Wolters, Erik" sort="Wolters, Erik" uniqKey="Wolters E" first="Erik" last="Wolters">Erik Wolters</name><affiliation><mods:affiliation>Research Institute Neurosciences Vrije Universiteit, VU University Medical Center, Amsterdam, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name><affiliation><mods:affiliation>Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey</mods:affiliation></affiliation></author><author><name sortKey="Onofrj, Marco" sort="Onofrj, Marco" uniqKey="Onofrj M" first="Marco" last="Onofrj">Marco Onofrj</name><affiliation><mods:affiliation>Gabriele D'Annunzio University Foundation, Pescara, Italy</mods:affiliation></affiliation></author><author><name sortKey="Hsu, Chuanchieh" sort="Hsu, Chuanchieh" uniqKey="Hsu C" first="Chuanchieh" last="Hsu">Chuanchieh Hsu</name><affiliation><mods:affiliation>Neuroscience Biostats Department, Novartis Pharmaceuticals, East Hanover, New Jersey, USA</mods:affiliation></affiliation></author><author><name sortKey="Tekin, Sibel" sort="Tekin, Sibel" uniqKey="Tekin S" first="Sibel" last="Tekin">Sibel Tekin</name><affiliation><mods:affiliation>Nervous System Clinical Research, Novartis Pharmaceuticals, East Hanover, New Jersey, USA</mods:affiliation></affiliation></author><author><name sortKey="Lane, Roger" sort="Lane, Roger" uniqKey="Lane R" first="Roger" last="Lane">Roger Lane</name><affiliation><mods:affiliation>Nervous System Clinical Research, Novartis Pharmaceuticals, East Hanover, New Jersey, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:FF4664716C5C713577D1CEB95BD89D6BD466E804</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/mds.20700</idno><idno type="url">https://api.istex.fr/document/FF4664716C5C713577D1CEB95BD89D6BD466E804/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001C18</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Long‐term benefits of rivastigmine in dementia associated with Parkinson's disease: An active treatment extension study</title><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Innsbruck Medical University, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Wolters, Erik" sort="Wolters, Erik" uniqKey="Wolters E" first="Erik" last="Wolters">Erik Wolters</name><affiliation><mods:affiliation>Research Institute Neurosciences Vrije Universiteit, VU University Medical Center, Amsterdam, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name><affiliation><mods:affiliation>Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey</mods:affiliation></affiliation></author><author><name sortKey="Onofrj, Marco" sort="Onofrj, Marco" uniqKey="Onofrj M" first="Marco" last="Onofrj">Marco Onofrj</name><affiliation><mods:affiliation>Gabriele D'Annunzio University Foundation, Pescara, Italy</mods:affiliation></affiliation></author><author><name sortKey="Hsu, Chuanchieh" sort="Hsu, Chuanchieh" uniqKey="Hsu C" first="Chuanchieh" last="Hsu">Chuanchieh Hsu</name><affiliation><mods:affiliation>Neuroscience Biostats Department, Novartis Pharmaceuticals, East Hanover, New Jersey, USA</mods:affiliation></affiliation></author><author><name sortKey="Tekin, Sibel" sort="Tekin, Sibel" uniqKey="Tekin S" first="Sibel" last="Tekin">Sibel Tekin</name><affiliation><mods:affiliation>Nervous System Clinical Research, Novartis Pharmaceuticals, East Hanover, New Jersey, USA</mods:affiliation></affiliation></author><author><name sortKey="Lane, Roger" sort="Lane, Roger" uniqKey="Lane R" first="Roger" last="Lane">Roger Lane</name><affiliation><mods:affiliation>Nervous System Clinical Research, Novartis Pharmaceuticals, East Hanover, New Jersey, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-04">2006-04</date><biblScope unit="vol">21</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="456">456</biblScope><biblScope unit="page" to="461">461</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">FF4664716C5C713577D1CEB95BD89D6BD466E804</idno><idno type="DOI">10.1002/mds.20700</idno><idno type="ArticleID">MDS20700</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>cholinesterase inhibitor</term><term>dementia</term><term>long term</term><term>rivastigmine</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In patients with dementia associated with Parkinson's disease (PD), the efficacy and safety of rivastigmine, an inhibitor of acetylcholinesterase and butyrylcholinesterase, were previously demonstrated in a 24‐week double‐blind placebo‐controlled trial. Our objective was to determine whether benefits were sustained over the long term. Following the double‐blind trial, all patients were permitted to enter an active treatment extension study, during which they received rivastigmine 3–12 mg/day. Standard safety assessments were performed. Efficacy assessments included the Alzheimer's Disease Assessment Scale cognitive subscale (ADAS‐cog) and other measures of cognition, daily function, neuropsychiatric symptoms, and executive function. Of 433 patients who completed the double‐blind trial, 334 entered and 273 completed the active treatment extension. At 48 weeks, the mean ADAS‐cog score for the whole group improved by 2 points above baseline. Placebo patients switching to rivastigmine for the active treatment extension experienced a mean cognitive improvement similar to that of the original rivastigmine group during the double‐blind trial. The adverse event profile was comparable to that seen in the double‐blind trial. Long‐term rivastigmine treatment appeared well tolerated and may provide sustained benefits in dementia associated with PD patients who remain on treatment for up to 48 weeks. © 2005 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Werner Poewe MD</name><affiliations><json:string>Innsbruck Medical University, Innsbruck, Austria</json:string></affiliations></json:item><json:item><name>Erik Wolters MD, PhD</name><affiliations><json:string>Research Institute Neurosciences Vrije Universiteit, VU University Medical Center, Amsterdam, The Netherlands</json:string></affiliations></json:item><json:item><name>Murat Emre MD</name><affiliations><json:string>Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey</json:string></affiliations></json:item><json:item><name>Marco Onofrj MD</name><affiliations><json:string>Gabriele D'Annunzio University Foundation, Pescara, Italy</json:string></affiliations></json:item><json:item><name>Chuanchieh Hsu PhD</name><affiliations><json:string>Neuroscience Biostats Department, Novartis Pharmaceuticals, East Hanover, New Jersey, USA</json:string></affiliations></json:item><json:item><name>Sibel Tekin MD</name><affiliations><json:string>Nervous System Clinical Research, Novartis Pharmaceuticals, East Hanover, New Jersey, USA</json:string></affiliations></json:item><json:item><name>Roger Lane MD</name><affiliations><json:string>Nervous System Clinical Research, Novartis Pharmaceuticals, East Hanover, New Jersey, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>cholinesterase inhibitor</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dementia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>long term</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>rivastigmine</value></json:item></subject><language><json:string>eng</json:string></language><abstract>In patients with dementia associated with Parkinson's disease (PD), the efficacy and safety of rivastigmine, an inhibitor of acetylcholinesterase and butyrylcholinesterase, were previously demonstrated in a 24‐week double‐blind placebo‐controlled trial. Our objective was to determine whether benefits were sustained over the long term. Following the double‐blind trial, all patients were permitted to enter an active treatment extension study, during which they received rivastigmine 3–12 mg/day. Standard safety assessments were performed. Efficacy assessments included the Alzheimer's Disease Assessment Scale cognitive subscale (ADAS‐cog) and other measures of cognition, daily function, neuropsychiatric symptoms, and executive function. Of 433 patients who completed the double‐blind trial, 334 entered and 273 completed the active treatment extension. At 48 weeks, the mean ADAS‐cog score for the whole group improved by 2 points above baseline. Placebo patients switching to rivastigmine for the active treatment extension experienced a mean cognitive improvement similar to that of the original rivastigmine group during the double‐blind trial. The adverse event profile was comparable to that seen in the double‐blind trial. Long‐term rivastigmine treatment appeared well tolerated and may provide sustained benefits in dementia associated with PD patients who remain on treatment for up to 48 weeks. © 2005 Movement Disorder Society</abstract><qualityIndicators><score>5.627</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1443</abstractCharCount><pdfWordCount>3251</pdfWordCount><pdfCharCount>21969</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>198</abstractWordCount></qualityIndicators><title>Long‐term benefits of rivastigmine in dementia associated with Parkinson's disease: An active treatment extension study</title><genre><json:string>Serial article</json:string></genre><host><volume>21</volume><pages><total>6</total><last>461</last><first>456</first></pages><issn><json:string>0885-3185</json:string></issn><issue>4</issue><subject><json:item><value>Research Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2006</publicationDate><copyrightDate>2006</copyrightDate><doi><json:string>10.1002/mds.20700</json:string></doi><id>FF4664716C5C713577D1CEB95BD89D6BD466E804</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/FF4664716C5C713577D1CEB95BD89D6BD466E804/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/FF4664716C5C713577D1CEB95BD89D6BD466E804/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/FF4664716C5C713577D1CEB95BD89D6BD466E804/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Long‐term benefits of rivastigmine in dementia associated with Parkinson's disease: An active treatment extension study</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2006</date></publicationStmt><notesStmt><note>Novartis Pharma, Basel, Switzerland</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Long‐term benefits of rivastigmine in dementia associated with Parkinson's disease: An active treatment extension study</title><author><persName><forename type="first">Werner</forename><surname>Poewe</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: Department of Neurology, Medical University Innsbruck, Innsbruck, Austria</p></note><affiliation>Innsbruck Medical University, Innsbruck, Austria</affiliation></author><author><persName><forename type="first">Erik</forename><surname>Wolters</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Research Institute Neurosciences Vrije Universiteit, VU University Medical Center, Amsterdam, The Netherlands</affiliation></author><author><persName><forename type="first">Murat</forename><surname>Emre</surname><roleName type="degree">MD</roleName></persName><affiliation>Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey</affiliation></author><author><persName><forename type="first">Marco</forename><surname>Onofrj</surname><roleName type="degree">MD</roleName></persName><affiliation>Gabriele D'Annunzio University Foundation, Pescara, Italy</affiliation></author><author><persName><forename type="first">Chuanchieh</forename><surname>Hsu</surname><roleName type="degree">PhD</roleName></persName><affiliation>Neuroscience Biostats Department, Novartis Pharmaceuticals, East Hanover, New Jersey, USA</affiliation></author><author><persName><forename type="first">Sibel</forename><surname>Tekin</surname><roleName type="degree">MD</roleName></persName><affiliation>Nervous System Clinical Research, Novartis Pharmaceuticals, East Hanover, New Jersey, USA</affiliation></author><author><persName><forename type="first">Roger</forename><surname>Lane</surname><roleName type="degree">MD</roleName></persName><affiliation>Nervous System Clinical Research, Novartis Pharmaceuticals, East Hanover, New Jersey, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-04"></date><biblScope unit="vol">21</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="456">456</biblScope><biblScope unit="page" to="461">461</biblScope></imprint></monogr><idno type="istex">FF4664716C5C713577D1CEB95BD89D6BD466E804</idno><idno type="DOI">10.1002/mds.20700</idno><idno type="ArticleID">MDS20700</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2006</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>In patients with dementia associated with Parkinson's disease (PD), the efficacy and safety of rivastigmine, an inhibitor of acetylcholinesterase and butyrylcholinesterase, were previously demonstrated in a 24‐week double‐blind placebo‐controlled trial. Our objective was to determine whether benefits were sustained over the long term. Following the double‐blind trial, all patients were permitted to enter an active treatment extension study, during which they received rivastigmine 3–12 mg/day. Standard safety assessments were performed. Efficacy assessments included the Alzheimer's Disease Assessment Scale cognitive subscale (ADAS‐cog) and other measures of cognition, daily function, neuropsychiatric symptoms, and executive function. Of 433 patients who completed the double‐blind trial, 334 entered and 273 completed the active treatment extension. At 48 weeks, the mean ADAS‐cog score for the whole group improved by 2 points above baseline. Placebo patients switching to rivastigmine for the active treatment extension experienced a mean cognitive improvement similar to that of the original rivastigmine group during the double‐blind trial. The adverse event profile was comparable to that seen in the double‐blind trial. Long‐term rivastigmine treatment appeared well tolerated and may provide sustained benefits in dementia associated with PD patients who remain on treatment for up to 48 weeks. © 2005 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>cholinesterase inhibitor</term></item><item><term>dementia</term></item><item><term>long term</term></item><item><term>Parkinson's disease</term></item><item><term>rivastigmine</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2005-03-16">Received</change><change when="2005-06-12">Registration</change><change when="2006-04">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/FF4664716C5C713577D1CEB95BD89D6BD466E804/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="40"><doi origin="wiley" registered="yes">10.1002/mds.v21:4</doi><numberingGroup><numbering type="journalVolume" number="21">21</numbering><numbering type="journalIssue">4</numbering></numberingGroup><coverDate startDate="2006-04">April 2006</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="30" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.20700</doi><idGroup><id type="unit" value="MDS20700"></id></idGroup><countGroup><count type="pageTotal" number="6"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2005 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2005-03-16"></event><event type="manuscriptRevised" date="2005-06-03"></event><event type="manuscriptAccepted" date="2005-06-12"></event><event type="publishedOnlineEarlyUnpaginated" date="2005-10-14"></event><event type="firstOnline" date="2005-10-14"></event><event type="publishedOnlineFinalForm" date="2006-04-11"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.6 mode:FullText source:FullText result:FullText" date="2010-04-21"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">456</numbering><numbering type="pageLast">461</numbering></numberingGroup><correspondenceTo>Department of Neurology, Medical University Innsbruck, Innsbruck, Austria</correspondenceTo><objectNameGroup><objectName elementName="appendix">APPENDIX</objectName></objectNameGroup><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS20700.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="3"></count><count type="referenceTotal" number="17"></count><count type="wordTotal" number="3808"></count></countGroup><titleGroup><title type="main" xml:lang="en">Long‐term benefits of rivastigmine in dementia associated with Parkinson's disease: An active treatment extension study</title><title type="short" xml:lang="en">Rivastigmine in Dementia Associated with PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Werner</givenNames><familyName>Poewe</familyName><degrees>MD</degrees></personName><contactDetails><email>werner.poewe@uibk.ac.at</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Erik</givenNames><familyName>Wolters</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Murat</givenNames><familyName>Emre</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Marco</givenNames><familyName>Onofrj</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Chuanchieh</givenNames><familyName>Hsu</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Sibel</givenNames><familyName>Tekin</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Roger</givenNames><familyName>Lane</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="AT" type="organization"><unparsedAffiliation>Innsbruck Medical University, Innsbruck, Austria</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="NL" type="organization"><unparsedAffiliation>Research Institute Neurosciences Vrije Universiteit, VU University Medical Center, Amsterdam, The Netherlands</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="TR" type="organization"><unparsedAffiliation>Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="IT" type="organization"><unparsedAffiliation>Gabriele D'Annunzio University Foundation, Pescara, Italy</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="US" type="organization"><unparsedAffiliation>Neuroscience Biostats Department, Novartis Pharmaceuticals, East Hanover, New Jersey, USA</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="US" type="organization"><unparsedAffiliation>Nervous System Clinical Research, Novartis Pharmaceuticals, East Hanover, New Jersey, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">cholinesterase inhibitor</keyword><keyword xml:id="kwd2">dementia</keyword><keyword xml:id="kwd3">long term</keyword><keyword xml:id="kwd4">Parkinson's disease</keyword><keyword xml:id="kwd5">rivastigmine</keyword></keywordGroup><fundingInfo><fundingAgency>Novartis Pharma, Basel, Switzerland</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>In patients with dementia associated with Parkinson's disease (PD), the efficacy and safety of rivastigmine, an inhibitor of acetylcholinesterase and butyrylcholinesterase, were previously demonstrated in a 24‐week double‐blind placebo‐controlled trial. Our objective was to determine whether benefits were sustained over the long term. Following the double‐blind trial, all patients were permitted to enter an active treatment extension study, during which they received rivastigmine 3–12 mg/day. Standard safety assessments were performed. Efficacy assessments included the Alzheimer's Disease Assessment Scale cognitive subscale (ADAS‐cog) and other measures of cognition, daily function, neuropsychiatric symptoms, and executive function. Of 433 patients who completed the double‐blind trial, 334 entered and 273 completed the active treatment extension. At 48 weeks, the mean ADAS‐cog score for the whole group improved by 2 points above baseline. Placebo patients switching to rivastigmine for the active treatment extension experienced a mean cognitive improvement similar to that of the original rivastigmine group during the double‐blind trial. The adverse event profile was comparable to that seen in the double‐blind trial. Long‐term rivastigmine treatment appeared well tolerated and may provide sustained benefits in dementia associated with PD patients who remain on treatment for up to 48 weeks. © 2005 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Long‐term benefits of rivastigmine in dementia associated with Parkinson's disease: An active treatment extension study</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Rivastigmine in Dementia Associated with PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Long‐term benefits of rivastigmine in dementia associated with Parkinson's disease: An active treatment extension study</title></titleInfo><name type="personal"><namePart type="given">Werner</namePart><namePart type="family">Poewe</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Innsbruck Medical University, Innsbruck, Austria</affiliation><description>Correspondence: Department of Neurology, Medical University Innsbruck, Innsbruck, Austria</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Erik</namePart><namePart type="family">Wolters</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Research Institute Neurosciences Vrije Universiteit, VU University Medical Center, Amsterdam, The Netherlands</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Murat</namePart><namePart type="family">Emre</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Marco</namePart><namePart type="family">Onofrj</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Gabriele D'Annunzio University Foundation, Pescara, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Chuanchieh</namePart><namePart type="family">Hsu</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Neuroscience Biostats Department, Novartis Pharmaceuticals, East Hanover, New Jersey, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sibel</namePart><namePart type="family">Tekin</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Nervous System Clinical Research, Novartis Pharmaceuticals, East Hanover, New Jersey, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Roger</namePart><namePart type="family">Lane</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Nervous System Clinical Research, Novartis Pharmaceuticals, East Hanover, New Jersey, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2006-04</dateIssued><dateCaptured encoding="w3cdtf">2005-03-16</dateCaptured><dateValid encoding="w3cdtf">2005-06-12</dateValid><copyrightDate encoding="w3cdtf">2006</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">3</extent><extent unit="references">17</extent><extent unit="words">3808</extent></physicalDescription><abstract lang="en">In patients with dementia associated with Parkinson's disease (PD), the efficacy and safety of rivastigmine, an inhibitor of acetylcholinesterase and butyrylcholinesterase, were previously demonstrated in a 24‐week double‐blind placebo‐controlled trial. Our objective was to determine whether benefits were sustained over the long term. Following the double‐blind trial, all patients were permitted to enter an active treatment extension study, during which they received rivastigmine 3–12 mg/day. Standard safety assessments were performed. Efficacy assessments included the Alzheimer's Disease Assessment Scale cognitive subscale (ADAS‐cog) and other measures of cognition, daily function, neuropsychiatric symptoms, and executive function. Of 433 patients who completed the double‐blind trial, 334 entered and 273 completed the active treatment extension. At 48 weeks, the mean ADAS‐cog score for the whole group improved by 2 points above baseline. Placebo patients switching to rivastigmine for the active treatment extension experienced a mean cognitive improvement similar to that of the original rivastigmine group during the double‐blind trial. The adverse event profile was comparable to that seen in the double‐blind trial. Long‐term rivastigmine treatment appeared well tolerated and may provide sustained benefits in dementia associated with PD patients who remain on treatment for up to 48 weeks. © 2005 Movement Disorder Society</abstract><note type="funding">Novartis Pharma, Basel, Switzerland</note><subject lang="en"><genre>Keywords</genre><topic>cholinesterase inhibitor</topic><topic>dementia</topic><topic>long term</topic><topic>Parkinson's disease</topic><topic>rivastigmine</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>456</start><end>461</end><total>6</total></extent></part></relatedItem><identifier type="istex">FF4664716C5C713577D1CEB95BD89D6BD466E804</identifier><identifier type="DOI">10.1002/mds.20700</identifier><identifier type="ArticleID">MDS20700</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2005 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C18 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001C18 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:FF4664716C5C713577D1CEB95BD89D6BD466E804
|texte= Long‐term benefits of rivastigmine in dementia associated with Parkinson's disease: An active treatment extension study
}}
| This area was generated with Dilib version V0.6.23. |  |